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symptomatic vitreomacular adhesion resolution on visual fixation and 
macular sensitivity using microperimetry.
Methods: A total of 220 subjects were randomized into the OASIS 
study, from which 27 were enrolled into the MP-1 substudy (19 
ocriplasmin, 8 sham). The substudy was conducted at 3 sites with 
protocol-specified microperimetry instruments. Fixation-related data 
included location, degree of eccentricity, and quantitative fixation 
stability (eg, bivariate contour ellipse area). Retinal sensitivity-related 
data included the number of normally functioning and scotomatous 
points and mean sensitivity within various macular grid regions.
Results: Baseline (BL) characteristics of the MP-1 subset were 
largely similar to the OASIS study. The mean distance of the 
preferred fixation locus to the anatomic center decreased slightly 
after ocriplasmin injection from 1.32 degrees at BL to 1.11 degrees at 
Day (D) 7, returning to BL levels (1.28 degrees) by D28, compared 
to the sham group (1.19, 1.43, and 1.75 degrees at BL, D7, D28, 
respectively). This distance was identified as a predictor of VMT 
resolution (P=.023). In the ocriplasmin group, the median relative 
scotoma increased postinjection from 1.0 at BL to 6.0 at D7 before 
recovering to 1.0 at Month (M) 6, whereas more scotomas were 
detected in the sham group over time (3.5, 4.0, and 5.0 at BL, D7, 
and M6, respectively). Mean bivariate contour ellipse area decreased 
slightly after ocriplasmin injection, from 5.98 degrees squared at 
BL to 4.26 degrees squared at D7 and 5.38 degrees squared at D28, 
compared to sham (7.73, 7.41, and 8.85 degrees squared at BL, D7, 
and D28, respectively). Subjects with VMT resolution at D28 had 
lower bivariate contour area and less relative scotoma at BL than 
those without. Of the visual function parameters, correlations were 
strongest for contrast sensitivity followed by best-corrected visual 
acuity, with no anatomical correlations.
Conclusions: Despite the small sample size, the MP-1 substudy 
suggests that in the ocriplasmin group, fixation and sensitivity 
parameters tended to be better than in the sham group over time. 
Although sensitivity seemed to decrease from D7 to D28 (with more 
relative scotomatous points) in the ocriplasmin group, it recovered 
subsequently.
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Visual field deterioration in central 10 degrees after vitrectomy 
for macular diseases in patients with glaucoma
Shunsuke Tsuchiya, Tomomi Higashide, Kazuhisa Sugiyama. 
Ophthalmology and Visual Science, Kanazawa University Graduate 
School of Medical Science, Kanazawa, Japan.
Purpose: To investigate retinal sensitivity changes in the central 10 
degrees after vitrectomy for epiretinal membrane (ERM) or macular 
hole (MH) in patients with glaucoma.
Methods: Seventy-one eyes of 71 patients who underwent 
vitrectomy with internal limiting membrane (ILM) peeling for 
ERM or MH were included: glaucoma patients (G group), 29 eyes; 
non-glaucoma control group (C group), 42 eyes. The main outcome 
measure was postoperative visual field (VF) changes (5.3 ± 4.3 
months after surgery) in standard automated perimetry (Humphrey 
visual field analyzer II, SITA standard 10-2 program). For each test 
point, ≥5 dB decrease in total deviation postoperatively was defined 
as deterioration in G group. For C group, test points with probability 
<1% on a pattern deviation map of postoperative VF were deemed 
as deterioration. We also evaluated best-corrected visual acuity 
(BCVA) and ganglion cell complex (GCC) thickness in the central 
10 degrees by optical coherence tomography (RS-3000, NIDEK). VF 
and GCC thickness were analyzed in each sector; center, inner ring, 
and outer ring, defined by three concentric circles, 3.3°-, 10°- and 
20°-diameters. Preoperative and postoperative factors related to the 
mean deviation (MD) changes were identified using univariate and 
multivariate linear regression analysis.
Results: Postoperative MD was -9.4±6.7 dB in G group, and 
-1.1±1.1 dB in C group. Postoperative pattern standard deviation 
(PSD) was 8.7±5.0 dB in G group, and 1.4±0.6 dB in C group. In G 
group, postoperative MD and PSD were significantly deteriorated 
after surgery (P<0.01). The number of deteriorated test points was 
12.2±8.3 in G group and 1.4±2.2 in C group. Fourteen out of 68 
test points were deteriorated in >30% of 29 eyes in G group and 
were located in the nasal half of outer ring. In both groups, GCC 
thickness was significantly decreased after surgery (P<0.01), and 
its postoperative value of G group was significantly thinner than C 
group (P<0.01). BCVA was significantly improved after surgery in 
both groups (P<0.01). In G group, a multivariate regression analysis 
identified preoperative PSD as the associated factor for MD changes 
(β=-0.396, P=0.03).
Conclusions: In glaucomatous eyes with ERM or MH, retinal 
sensitivity in central 10 degrees, especially in the nasal half of outer 
ring, may deteriorate after vitrectomy with ILM peeling.
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Topline Results From Prospective, Double-masked, Placebo 
Controlled Phase 2 Clinical Study Evaluating Luminate® 
(ALG-1001) in Patients with Symptomatic Focal Vitreomacular 
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Purpose: To investigate the safety and efficacy of Luminate (ALG-
1001), a synthetic anti-angiogenic and vitreolytic oligopeptide, 
administered intravitreally in patients with focal vitreomacular 
adhesion (VMA) or vitreomacular traction (VMT).
Methods: Patients were randomly assigned to four groups. Group 1 
received intravitreal Luminate 2.0 mg, Group 2 received Luminate 
2.5 mg, Group 3 received Luminate 3.2 mg, and Group 4 (control) 
received an intravitreal injection of balanced salt solution. Intravitreal 
injections were administered monthly until VMA or VMT release was 
achieved for a total of 90 days with three maximum injections. VMA 
or VMT release was determined by optical coherence tomography 
(OCT) images read by Duke Reading Center. The primary endpoint 
of this study was observation of pharmacologic resolution of VMA 
by OCT, with VMA defined as vitreous adhesion to the macula within 
a 6mm central retinal field determined on OCT.
Results: One hundred and six patients from approximately 20 sites in 
the United States and Europe were included in this analysis. Sixty-
five percent of patients treated with the 3.2 mg dose of Luminate 
achieved release of VMA or VMT by Day 90 (p=0.0129), compared 
to 21% of those in the 2.5 mg group, 23% in the 2.0 mg group, and 
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10% of those in the placebo control group. For all groups, 48% of 
all releases occurred after the first injection, 32% occurred after the 
second injection, and 20% of all releases occurred after the third 
injection. The most commonly reported AEs were conjunctival 
hyperemia and sub-conjunctival hemorrhage at the injection site. 
There was no incidence of drug toxicity or significant intraocular 
inflammation, no afferent pupillary defects, and no evidence of retinal 
tears or detachments among all groups.
Conclusions: Data from this phase 2 VMA/VMT trial demonstrated 
that Luminate met its primary endpoint of VMA or VMT release. 
Luminate was well-tolerated in all Luminate dosing groups.
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Insight into lamellar macular holes: two distinct clinical entities
Andrea Govetto, Hamid Hosseini, Steven D. Schwartz, 
Jean Pierre Hubschman. RETINA, STEIN EYE INSTITUTE, 
LOS ANGELES, CA.
Purpose: To investigate whether lamellar macular holes can be 
divided into different subgroups.
Methods: In this institutional study, clinical charts and Spectral-
Domain Optical Coherence Tomography (OCT) images of 112 eyes 
of 100 consecutive patients diagnosed with lamellar macular hole 
were reviewed.
In OCT imaging, the presence of lamellar macular hole was defined 
according to the following findings: presence of irregular foveal 
contour, separation of the layers of the neurosensory retina, and the 
absence of full thickness macular defect.
Mean outcome was the morphological and functional characterization 
of different subtypes of macular hole.
Results: Two different subtypes of lamellar macular hole were 
identified: tractional and degenerative. The first type, tractional, had 
a “moustache” appearance, was diagnosed in 47 eyes (42%), and 
was characterized by the schisic separation of neurosensory retina 
between outer plexiform and outer nuclear layers. It often presented 
with an intact ellipsoid layer (98%, 46/47) and was associated with 
tractional epiretinal membranes and/or vitreo-macular traction (97%, 
45/47). The second type, degenerative, had a “top hat” appearance, 
was diagnosed in 53 eyes (47%), and its distinctive traits included the 
presence of intra-retinal cavitation that could affect all retinal layers. 
It was often associated with non-tractional epiretinal proliferation 
(98%, 52/53) and a retinal “bump” (87%, 46/53). Moreover, it often 
presented with early ellipsoidal zone defect (95%, 50/53) and its 
pathogenesis, although chronic, and progressive remains poorly 
understood.
Twelve eyes (11%) shared common features with both tractional and 
degenerative lamellar macular holes and were classified as mixed 
lesions.
Conclusions: Degenerative and tractional lamellar macular holes 
are two distinct clinical entities. A revision of the current concept of 
lamellar macular holes is needed.
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Factors Associated with Development of Dissociated Optic Nerve 
Fiber Layer (DONFL) Appearance in the PIONEER Study
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Purpose: The cause of the Dissociated Optic Nerve Fiber Layer 
(DONFL) appearance after membrane peeling for vitreomacular 
interface (VMI) disorders remains unknown. We used intraoperative 
OCT (iOCT) to examine the relationship between retinal alterations 
during membrane peeling and postoperative development of DONFL 
appearance.
Methods: This was a post-hoc analaysis of eyes undergoing 
membrane peeling for VMI disorders in the PIONEER study, an IRB-
approved prospective study examining iOCT in ophthalmic surgery. A 
microscope mounted SD-OCT probe (Bioptigen) was used to obtain 
pre-incision and post-peel iOCT images. Exclusion criteria included 
lack of follow-up OCT from 3-12 months postoperatively and poor 
iOCT or postoperative OCT image quality. iOCT images were 
assessed for microarchitectural changes including inner, middle, and 
outer retinal thickness. Clinical variables assessed included indication 
for surgery and membrane peeling technique (e.g., diamond-dusted 
membrane scraper [DDMS], forceps). Primary outcome was 
development of DONFL appearance on 6 month follow-up SD-OCT.
Results: Ninety-nine eyes were included in the study. Preoperative 
diagnosis included epiretinal membrane (ERM) in 54 eyes (55%), 
macular hole (MH) in 41 eyes (42%), and vitreomacular traction 
syndrome (VMT) in 3 eyes (3%). The OCT-based prevalence of DONFL 
appearance at 6 months was 33%. Prevalence of DONFL appearance 
was 9.3% in eyes with ERM and 63.4% in eyes with MH. In eyes 
where forceps alone were used for membrane peeling, prevalence of 
DONFL appearance was 30.4%, while in eyes where DDMS was used, 
prevalence was 34.6% (p=0.66). Quantitative analysis of iOCT and acute 
postoperative retinal layer changes identified increased inner retinal 
layer thickness as a significant factor associated with postoperative 
development of DONFL appearance (p = 0.02).
